Join us on Tuesday, July 16 to hear from MAPS leaders
We’re excited to invite you to an exclusive webinar, “MAPS, MDMA & Beyond,” where you will have the opportunity to hear from leaders at MAPS about how we’re approaching this pivotal period following the FDA Advisory Committee hearing. As we, along with the entire psychedelic ecosystem, eagerly await the FDA’s decision on Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy for PTSD, this is a momentous time for all of us.
Event Details:
Date: Tuesday, July 16th
Time: 4:00 pm PDT
Duration: 1 Hour
Join MAPS leaders Kris Lotlikar, Ismail Ali, J.D., Allison Coker, Ph.D., and Betty Aldworth to delve into the approaches and strategies MAPS is engaging during this critical juncture. After 38 years of pioneering psychedelic research, policy reform, and cultural transformation, MAPS has laid the groundwork for a breakthrough era in psychedelics. Now, as we look ahead, what’s next for MAPS?
In this hour-long webinar, we’ll discuss:
- How we’re thinking about MDMA-assisted therapy for PTSD and the anticipated FDA decision.
- What we’re doing today to achieve a post-prohibition psychedelic future.
- The impact of policy reform and cultural shifts on the future of psychedelics.
- Your questions and insights during a live Q&A session.
Don’t miss this chance to gain inside knowledge and connect with the MAPS leaders who are shaping the future of psychedelic research, policy, and culture. We look forward to your participation in this event and sharing with you the exciting developments that lie ahead for MAPS and the psychedelic community.
MAPS’ Resources